IW-3718
C3718-301
Phase 3 small_molecule terminated
Quick answer
IW-3718 for Gastroesophageal Reflux Disease (GERD) is a Phase 3 program (small_molecule) at IRONWOOD PHARMACEUTICALS INC with 2 ClinicalTrials.gov record(s).
Program details
- Company
- IRONWOOD PHARMACEUTICALS INC
- Indication
- Gastroesophageal Reflux Disease (GERD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated